Surgical treatment of pancreatic cancer: The role of adjuvant and multimodal therapies

Cachexia Worsens Prognosis in Patients with Resectable Pancreatic Cancer

“…6,[8][9][10][11][12] According to recent publications, the standard treatment regime in resectable pancreatic cancer should be a potentially curative resection followed by adjuvant systemic chemotherapy. 7,13,14 However, most patients develop local or distant tumor recurrence within 2 years after resection, 2,15-17 often associated with rapid development of a cachexia syndrome.…”

“…1 Ductal pancreatic adenocarcinoma is characterized by retroperitoneal and perineural infiltration, early formation of multiple distant metastases, and resistance to most adjuvant treatment regimes. [2][3][4][5][6][7] Surgical resection is the patient's only hope for cure and offers a significantly improved prognosis, with a median survival after resection of 14-20 months and 5-year survival rates up to 25%. 6,[8][9][10][11][12] According to recent publications, the standard treatment regime in resectable pancreatic cancer should be a potentially curative resection followed by adjuvant systemic chemotherapy.…”

Reduced α-Dystroglycan Expression Correlates with Shortened Patient Survival in Pancreatic Cancer

“…Due to early local invasion and distant metastasis, pancreatic ductal adenocarcinoma (PDAC) is a lethal disease with an overall survival rate of less than 5% [19] and about 20%-25% in resected patients [20][21][22]. PDAC is the result of a step-wise progression from ductal cells (or transdifferentiated acinar/centroacinar cells) through stages of pancreatic intraepithelial neoplasia (PanIN) to invasive cancer [23].…”

Identifying pancreatic cancer patients for targeted treatment: the challenges and limitations of the current selection process and vision for the future

“…Identifying pancreatic cancer patients for targeted treatment: the challenges and limitations of the current selection process and vision for the future Shayna Identifying pancreatic cancer patients for targeted treatment: the challenges and limitations of the current selection process and vision for the future 1…”